Lōkahi's One-Shot Strategy: De-risking its Pain Drug for Market Success

RUTHERFORD, NJ – July 29, 2026 – In a move that could significantly alter the treatment landscape for osteoarthritis pain, Lōkahi Therapeutics has announced a pivotal shift in the development of its lead therapeutic candidate, LT-100. The company is advancing a strategy to simplify the drug's administration from a burdensome regimen of up to 15 intradermal injections per visit to a single, more convenient subcutaneous shot. This decision, backed by positive nonclinical data and early discussions with the U.S. Food and Drug Administration (FDA), represents a critical step in translating a promising therapeutic prototype into a commercially viable product.

LT-100, a non-opioid biologic derived from purified honey bee venom, is being developed to treat inflammation and pain associated with osteoarthritis. While bee venom has been used for centuries in traditional medicine, Lōkahi is applying modern pharmaceutical rigor to an asset that was previously approved and used in South Korea. The announcement signals a major milestone in its U.S. development, focusing not just on clinical efficacy, but on a crucial factor for market success: patient experience.

A Patient-Centric Pivot with Major Commercial Implications

For any chronic condition, treatment adherence is a major hurdle. For osteoarthritis patients who would have faced up to 15 separate injections in a single clinical visit, the barrier is particularly high. Lōkahi's strategic pivot directly addresses this challenge, aiming to drastically improve quality of life and treatment compliance. As Lōkahi's Chief Executive Officer, Erik Emerson, stated, "The difference between 15 injections and one injection speaks for itself."

This simplification is more than just a convenience; it's a powerful commercial differentiator. In the crowded market for pain management, which is actively seeking effective non-opioid alternatives, a therapy's administration route can make or break its market uptake. A single-injection format reduces patient anxiety, minimizes discomfort, and lessens the time and logistical burden on both patients and healthcare providers. According to industry analysts, this enhanced patient-centric design could support a stronger value proposition, potentially leading to broader adoption and a more favorable pricing strategy upon approval.

By prioritizing a less invasive delivery method, Lōkahi is positioning LT-100 to compete more effectively against existing treatments, which range from daily oral NSAIDs with potential side effects to other types of injections. If the upcoming clinical trials confirm that the single shot is as effective as the original multi-injection method, the company will have unlocked a significant competitive advantage long before the product hits the pharmacy shelf.

Navigating the Regulatory Gauntlet

A change in a drug's administration route is not a trivial matter for regulators. It requires careful planning and robust data. Lōkahi appears to be methodically checking these boxes, a key insight for investors tracking the company's path from development to revenue. The company disclosed it held a Type C meeting with the FDA in May 2026 to discuss its proposed clinical strategy. These meetings are a vital tool for de-risking development, allowing companies to gain regulatory feedback early and align on the path forward.

Following that discussion, Lōkahi completed a nonclinical minipig study to compare the two injection methods. The positive results from this study provided the scientific rationale needed to proceed. "The Type C meeting helped define a path forward," Emerson noted. "We then completed the work necessary to evaluate that path, and the results give us confidence to move toward clinical evaluation of this simplified administration strategy."

With this groundwork laid, Lōkahi is targeting the initiation of a clinical trial for the single-injection approach as early as the fourth quarter of 2026. This is a clear, actionable milestone for observers. The company anticipates an initial data readout from this study in the first half of 2027, which will be a pivotal moment in validating this streamlined approach. Successfully navigating this phase would not only advance LT-100 but also demonstrate the effectiveness of Lōkahi’s development capabilities.

The Science Behind the Simplification

At the heart of this strategic shift is a complex pharmacological question: can a single subcutaneous (SC) injection deliver the drug into the body as effectively as 15 shallow, intradermal (ID) injections? The two methods involve different layers of tissue and can result in different rates of drug absorption. The primary goal, as explained by Susan Kramer, Senior Vice President of Development at Lōkahi, was straightforward. “We wanted to understand whether subcutaneous administration could achieve systemic exposure consistent with prior clinical experience using intradermal administration,” she said.

Achieving this consistency is paramount. It ensures that the wealth of historical clinical data gathered using the multi-injection method remains relevant, potentially saving the company from having to repeat years of foundational studies. The minipig study was designed to bridge this gap, providing crucial data showing that the single SC shot could indeed produce the desired drug levels in the bloodstream. This finding provides the scientific foundation for the upcoming human trials and gives regulators confidence that the change is based on sound science, not just commercial aspiration.

An Overlooked Asset in Glucotrack’s Diversified Portfolio

The story of LT-100 is also a story of corporate strategy. Lōkahi is a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), a company primarily known for developing a long-term implantable continuous blood glucose monitor for people with diabetes. The parent company's foray into biopharmaceuticals through Lōkahi represents a calculated diversification play.

Lōkahi operates as a “capital-efficient biopharmaceutical platform company,” using its proprietary 'ai² platform' to identify and advance “overlooked therapeutic assets.” LT-100 is a prime example of this model in action. With a history of approval and use in South Korea, the drug is not a brand-new discovery but an asset with existing human data that can be leveraged to streamline its path through the rigorous U.S. regulatory process. This model aims to reduce the time, cost, and risk typically associated with early-stage drug development.

For Glucotrack investors, the progress with LT-100 demonstrates the potential of this strategy to create significant value outside of its core diabetes business. The successful commercialization of LT-100 would not only open up a new revenue stream in the massive osteoarthritis market but also validate Lōkahi's entire business model of turning overlooked assets into profitable therapies. The upcoming clinical evaluation of the single-injection formulation is therefore a critical test for both the drug and the strategic vision behind it.